{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["CD19 t-haNK","rituximab"],["CD19 t-haNK","nogapendekin alfa inbakicept (N-803)","rituximab"]],"indication":"relapsed/refractory non-Hodgkin lymphoma","name":"QUILT-3.092","nct_id":"NCT05618925","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=quilt-3-092-nct05618925. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Subjects in both cohorts will initially receive lymphodepleting chemotherapy followed by a single 4-week cycle of the CD19 t-haNK single-agent regimen. Following a 1-week rest period, subjects will then receive lymphodepleting chemotherapy followed by a single 4-week cycle of CD19 t-haNK in combination with rituximab","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Subjects in both cohorts will initially receive lymphodepleting chemotherapy followed by a single 4-week cycle of the CD19 t-haNK single-agent regimen. Following a 1-week rest period, subjects will then receive lymphodepleting chemotherapy followed by a single 4-week cycle of CD19 t-haNK in combination with rituximab (cohort A) or in combination with rituximab and N-803 (cohort B).","label":"Arm B","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-03-15","type":"ESTIMATED"},"conditions":["Non Hodgkin's Lymphoma Refractory/Relapsed"],"enrollment":{"count":20,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"N803","otherNames":["Anktiva"],"type":"DRUG"},{"name":"CD19t-haNK suspension","otherNames":[],"type":"BIOLOGICAL"},{"name":"Cyclophosphamide","otherNames":["Cytoxan"],"type":"DRUG"},{"name":"Fludarabine","otherNames":["Fludara"],"type":"DRUG"},{"name":"Rituximab","otherNames":["Rituxan"],"type":"DRUG"}],"last_update":"2026-04-01","lead_sponsor":"ImmunityBio, Inc.","official_title":"Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma.","overall_status":"RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2026-05-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Primary Outcome Measures","timeFrame":"within 30 days after each cell infusion"}],"references":[],"start_date":{"date":"2025-08-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma","url":"https://clinicaltrials.gov/study/NCT05618925"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/quilt-3-092-nct05618925"}